The latest announcement is out from 4DMedical Ltd ( (AU:4DX) ).
4DMedical Limited announced its half-year results, highlighting a significant increase in operating revenue by 265.3% to $3.8 million, driven by strong support from institutional investors and the launch of a Share Purchase Plan. The company has expanded its operations to 301 sites, delivering over 8,000 scans in the first half of FY2025, and has made substantial progress in commercializing its products, including FDA clearance for its eighth commercial product. The company’s strategic partnerships and recent contract signings are expected to further enhance its revenue stream.
More about 4DMedical Ltd
4DMedical Limited is a respiratory imaging technology company that specializes in providing advanced imaging solutions for lung health. The company focuses on delivering Software-as-a-Service (SaaS) products and operates globally with a significant presence in both the United States and Australia.
YTD Price Performance: -13.54%
Average Trading Volume: 936,042
Technical Sentiment Consensus Rating: Buy
Current Market Cap: A$171.9M
Find detailed analytics on 4DX stock on TipRanks’ Stock Analysis page.